Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors

Cancer Cell - United States
doi 10.1016/j.ccr.2011.08.014
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Personalized Medicine: Exploiting Druggable Vulnerabilities for KRAS-driven Lung Cancer

Oncoscience
Cancer ResearchOncology
2018English

A Small Molecule Approach to Degrade RAS With EGFR Repression Is a Potential Therapy for KRAS Mutation-Driven Colorectal Cancer Resistance to Cetuximab

Experimental and Molecular Medicine
BiochemistryMedicineClinical BiochemistryMolecular BiologyMolecular Medicine
2018English

Exploiting SCADA Vulnerabilities Using a Human Interface Device

International Journal of Advanced Computer Science and Applications
Computer Science
2015English

MA27.10 EGFR-Targeted Therapy Alters the Tumor Microenvironment in EGFR-Driven Lung Tumors: Rationale for Combination Therapies

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy

Journal of Nanomedicine & Nanotechnology
2013English

mRNA Splicing Variants: Exploiting Modularity to Outwit Cancer Therapy

Cancer Research
Cancer ResearchOncology
2013English

Exploiting Theory to Develop Practice in Biological Education

Journal of Biological Education
AgriculturalEducationBiological Sciences
2018English

Targeting Ras-Driven Cancer Cell Survival and Invasion Through Selective Inhibition of DOCK1

Cell Reports
BiochemistryGeneticsMolecular Biology
2017English

Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

Clinical Cancer Research
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy